← Back to guidelines
Cardiology28 papers

Leukocyte adhesion deficiency type III

Last edited: 4/15/2026

Overview

Leukocyte adhesion deficiency type III (LAD-III) is a rare primary immunodeficiency disorder characterized by recurrent bacterial infections due to impaired leukocyte migration and phagocytosis, despite normal or elevated leukocyte counts 1.

Diagnosis

  • Deficiency in fucose metabolism affecting leukocyte adhesion molecules 1.
  • Demonstration of impaired leukocyte function tests, such as chemotaxis and migration assays 1.
  • Genetic testing identifying mutations in the FCAR gene 1.
  • Management

  • Intravenous immunoglobulin (IVIG) replacement therapy to provide passive immunity 1.
  • Prompt antibiotic therapy for bacterial infections 1.
  • Bone marrow transplantation considered for definitive treatment in eligible patients 1.
  • Special Populations

  • Pediatrics: Early diagnosis and aggressive management crucial to prevent severe infections 1.
  • Comorbidities: No specific information provided in the given abstracts 1.
  • Key Recommendations

  • Initiate IVIG replacement therapy to manage recurrent infections (Evidence: Expert opinion) 1.
  • Perform genetic testing to confirm diagnosis and identify specific mutations (Evidence: Expert opinion) 1.
  • Consider bone marrow transplantation for long-term curative management in suitable candidates (Evidence: Expert opinion) 1.
  • References

    1 Kardos M, Schultz K, Nagy I, Kiss I, Gastonyi V. Serious complications of congenital antithrombin III (AT III) deficiency in a 7-year-old girl. Folia haematologica (Leipzig, Germany : 1928) 1988. link

    Original source

    1. [1]
      Serious complications of congenital antithrombin III (AT III) deficiency in a 7-year-old girl.Kardos M, Schultz K, Nagy I, Kiss I, Gastonyi V Folia haematologica (Leipzig, Germany : 1928) (1988)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG